Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects
Condition: Type 2 Diabetes MellitusInterventions: Drug: Bumetanide; Drug: DapagliflozinSponsor: AstraZenecaCompleted - verified March 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials